Skip to content

Wearable Technology-Supported Exercise Program for Fatigue and Quality of Life in Pediatric Cancer Patients (WE-EX PedsCa)

Effect of a Wearable Technology-Supported Exercise Program on Fatigue and Health-Related Quality of Life in Pediatric Cancer Patients: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07337681
Acronym
WE-EX PedsCa
Enrollment
50
Registered
2026-01-13
Start date
2026-03-31
Completion date
2026-05-31
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cancer, Cancer-related Fatigue, Quality of Life, Exercise

Keywords

Pediatric oncology, adolescent cancer, wearable technology, exercise intervention, physical activity, cancer-related fatigue, health-related quality of life, mobile health, digital exercise program

Brief summary

Children and adolescents receiving cancer treatment often experience fatigue, reduced physical activity, and decreased quality of life. Although exercise has been shown to reduce these problems, maintaining regular and safe physical activity during cancer treatment can be difficult due to treatment side effects, safety concerns, and limited access to supervised programs. This study aims to evaluate the feasibility, safety, and effectiveness of a wearable technology-supported exercise program on fatigue and health-related quality of life in pediatric cancer patients aged 13 to 18 years. Participants will be randomly assigned to either an intervention group or a control group. The intervention group will participate in an 8-week structured exercise program delivered through a mobile application, including video-guided exercise sessions performed three times per week and monitored continuously using a wearable activity tracker. The control group will receive standard care and will wear the activity tracker for passive monitoring only. Fatigue and quality of life will be assessed at baseline, mid-intervention, and after completion of the program. Physical activity, heart rate, sleep patterns, and adherence to the exercise program will be objectively monitored using wearable devices. The findings from this study are expected to provide evidence on whether a digitally delivered, wearable-supported exercise program is a feasible and beneficial approach to improving well-being in children and adolescents undergoing cancer treatment.

Detailed description

Detailed Description This study is a single-center, parallel-group, randomized controlled trial designed to evaluate the feasibility, safety, and efficacy of a wearable technology-supported structured exercise program on fatigue and health-related quality of life (HRQoL) in pediatric cancer patients aged 13-18 years who are receiving active cancer treatment. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group using stratified randomization based on age, sex, and cancer diagnosis. Allocation concealment will be ensured through a secure electronic randomization system. Treating pediatric oncologists will remain blinded to group allocation. Study Intervention Participants in the intervention group will take part in an 8-week structured exercise program delivered through a mobile application. The program consists of video-guided exercise sessions performed three times per week, with each session lasting approximately 40 minutes. The exercise protocol includes warm-up, aerobic, strengthening, coordination, and cool-down components and is designed to be low to moderate intensity, adaptable to individual clinical conditions, and safely performed either in seated or standing positions. Exercise content was developed by a multidisciplinary team and incorporates engagement strategies such as animated guidance and gamification elements to support adherence. Participants in the control group will receive standard care without a structured exercise intervention. Both groups will wear a commercially available wearable activity tracker throughout the study period to allow objective monitoring of physical activity and physiological parameters. In the control group, the device will be used for passive monitoring only. Monitoring and Assessments Fatigue and health-related quality of life will be assessed at baseline (week 0), mid-intervention (week 4), and post-intervention (week 8) using validated, age-appropriate instruments administered through the mobile platform. Objective physical activity data, including daily step counts, active minutes, heart rate, sleep duration and patterns, and device wear time, will be continuously collected via wearable devices and securely integrated into the study database. Functional exercise capacity will be assessed using the 6-minute walk test at the same three time points. Engagement and adherence to the intervention will be evaluated using app-based metrics such as exercise session completion, frequency of use, and participation consistency. Safety and Feasibility Participants will be monitored throughout the study for adverse events related to exercise participation. A pediatric hematology-oncology physician and specialist nurse will oversee clinical safety. Feasibility outcomes will include recruitment rate, retention rate, adherence to exercise sessions, and completeness of wearable-derived data. Data Analysis Analyses will be conducted according to the intention-to-treat principle. Changes in fatigue and HRQoL over time and between groups will be examined using appropriate repeated-measures statistical methods based on data distribution. Secondary analyses will explore changes in physical activity, sleep parameters, and engagement metrics. Effect sizes will be calculated to inform the design of future multicenter trials. Study Purpose This trial aims to generate preliminary evidence on the clinical applicability of integrating wearable technology-supported exercise into pediatric oncology care. The findings are intended to inform larger-scale studies and contribute to the development of scalable, evidence-based digital exercise interventions for children and adolescents undergoing cancer treatment.

Interventions

OTHERWearable Technology-Supported Exercise Program

Wearable Technology-Supported Exercise Program

Usual pediatric oncology care with passive wearable monitoring and no structured exercise guidance.

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

This is an open-label study. Due to the nature of the exercise intervention, participants and study personnel are aware of group assignment. Treating pediatric oncologists are not informed of allocation and are not involved in outcome assessments.

Intervention model description

This is a single-center, parallel-group randomized controlled trial in which participants are assigned in a 1:1 ratio to either an intervention group receiving a wearable technology-supported structured exercise program or a control group receiving standard care with passive monitoring. Outcomes are assessed concurrently in both groups over an 8-week study period.

Eligibility

Sex/Gender
ALL
Age
13 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Aged 13 to 18 years. * Diagnosed with cancer and followed at a pediatric hematology-oncology clinic. * Currently receiving active cancer treatment and has completed at least one cycle of chemotherapy. * Clinically stable and medically cleared by the treating physician to participate in low-to-moderate intensity exercise. * Able to understand instructions and communicate verbally. * Willing to participate in at least 75% of the prescribed exercise sessions. * Written informed consent obtained from a parent or legal guardian and assent obtained from the participant.

Exclusion criteria

* Presence of acute infection, uncontrolled cardiac or pulmonary disease, respiratory failure, or uncontrolled hypertension. * Severe neurological, psychiatric, or musculoskeletal conditions that limit safe participation in exercise. * Persistent thrombocytopenia (\<10,000/µL) or known coagulation disorders. * Uncontrolled seizure disorders. * Central nervous system metastases. * Any medical or psychological condition deemed by the treating physician to contraindicate exercise participation or compromise study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Cancer-Related FatigueBaseline (week 0), mid-intervention (week 4), and post-intervention (week 8)Cancer-related fatigue will be assessed using a validated multidimensional fatigue scale including physical, cognitive, and general fatigue subscales. Higher scores indicate greater fatigue severity.

Secondary

MeasureTime frameDescription
Health-Related Quality of LifeBaseline (week 0), mid-intervention (week 4), and post-intervention (week 8)Health-related quality of life will be measured using the Pediatric Quality of Life Inventory (PedsQL 4.0) Cancer Module, which assesses physical, emotional, social, and school functioning.

Other

MeasureTime frameDescription
Exercise AdherenceThroughout the 8-week intervention periodExercise adherence will be evaluated based on the proportion of prescribed exercise sessions completed by participants in the intervention group, as recorded through the mobile application and wearable activity tracker.

Contacts

Primary ContactYagmur Berktas, phd candidate
yagmurberktas07@gmail.com+90 5442753844
Backup Contactrejin kebudi, professor
rejinkebudi@yahoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026